National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: The relationship between Context, Evidence and Links

Health Research Policy and Systems

Volumn 9, Issue SUPPL. 1, 2011, Pages

  Hutchinson, Eleanor ^a   Parkhurst, Justin ^a   Phiri, Sam ^b   Gibb, Di M ^c   Chishinga, Nathaniel ^d   Droti, Benson ^e   Hoskins, Susan ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KAMUZU CENTRAL HOSPITAL   (Malawi)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITY OF ZAMBIA   (Zambia)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CLINICAL RESEARCH; COMPARATIVE STUDY; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION PREVENTION; MALAWI; UGANDA; ZAMBIA;

EID: 79958824364     PISSN: None     EISSN: 14784505     Source Type: Journal    
DOI: 10.1186/1478-4505-9-S1-S6     Document Type: Article

References (36)

1. Lin V. Evidence-based health policy. 2003, Oxford: Oxford University Press, Gibson B.
2. Walt G, Gilson L. Reforming the health sector in developing countries: the central role of policy analysis. Health Policy and Planning 1994, 9:353-370. 10.1093/heapol/9.4.353, 10139469.
3. Crewe E, Young J. Bridging research and policy: context, evidence and links. Working paper 173 2002, London: ODI.
4. Gilson L, Raphaely N. The terrain of health policy analysis in low and middle income countries: a review of published literature 1994-2007. Health Policy Plan 2008, 23:294-307. 10.1093/heapol/czn019, 2515407, 18650209.
5. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double blind randomised placebo-controlled trial. The Lancet 2004, 364:1865-1871.
6. Grimwade K, Swingler GH. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database of Systematic Reviews 2003,
7. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. The Lancet 1999, 353:1469-1475.
8. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R, . group C-CS Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Cote d'Ivoire: a randomised trial. The Lancet 1999, 252:1463-1468. group C-CS.
9. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001, 15:1143-1148. 10.1097/00002030-200106150-00009, 11416716.
10. Badri M, Maartens G, Wood R, Ehrlich R. Co-trimoxazole in HIV-1infection (Letter). The Lancet 1999, 354:334.
11. Boeree MJ, Sauvageot D, Banda HT, Harries AD, Zijlstra EE. Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Tropical Medicine and International Health 2005, 10:723-733. 10.1111/j.1365-3156.2005.01433.x, 16045458.
12. Grimwade K, Sturmc AW, Nunn AJ, Mbatha D, Zungua D, Gilkse CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005, 19:163-168. 10.1097/00002030-200501280-00008, 15668541.
13. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 354:1428-1434.
14. Mermin J, Lule J, Ekwaru JP, Downing R, Hughes P, Bunnell R, Malamba S, Ransom R, Kaharuza F, Coutinho A, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005, 19:1035-1042. 10.1097/01.aids.0000174449.32756.c7, 15958834.
15. Mwaungulu FBD, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, Harries AD, Glynn JR, Fine PEM. Cotrimoxazole prophylaxis reduced mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bulletin of the World Health Organization 2004, 82:354-363. 2622842, 15298226.
16. Watera C, Todd J, Muwonge R, Whitworth J, Nakiyingi-Miiro J, Brink A, Miiro G, Antvelink L, Kamali A, French N, Mermin J. Feasibility and Effectiveness of Cotrimoxazole Prophylaxis for HIV-1-Infected Adults Attending an HIV/AIDS Clinic in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 2006, 42:373-378. 310.1097/1001.qai.0000221679.0000214445.0000221671b.
17. Zachariah R, Spielmann MP, Chinjia C, Gomani P, Arendt V, Hargreaves NJ, Salaniponi FM, Harries AD. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003, 17:1053-1061. 10.1097/00002030-200305020-00015, 12700456.
18. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, Hawkins N, Merry C, Barry MG, Chintu C, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS 2008, 22:749-757. 10.1097/QAD.0b013e3282f43519, 18356605.
19. Chimzizi R, Gausi F, Bwanali A, Mbalume D, Teck R, Gomani P, Zachariah R, Zuza W, Malombe R, Salaniponi FM. Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi. The International Journal of Tuberculosis and Lung Disease 2004, 8:579-585.
20. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. The International Journal of Tuberculosis and Lung Disease 2004, 8:938-944.
21. Anglaret X, Eholie S. Editorial: Cotrimoxazole for HIV infected adults reduces mortality even where bacterial resistance is high. British Medical Journal 2008, 337:184.
22. Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bulletin of the World Health Organization 2010, 88(4):241-320.
23. Zachariah R, Harries AD, Luo C, Bachman G, Graham SM. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infectious Diseases 2007, 7:686-693. 10.1016/S1473-3099(07)70239-6, 17897611.
24. Court J, Young J. Bridging research and policy: insights from 50 case studies. Working Paper 213 2003, London: ODI.
25. Solesbury W. Sustainable Livelihoods: A Case Study of the Evolution of DFID Policy. Working Paper 217 2003, London: ODI.
26. Theobald S, Taegtmeyer M, Squire S, Crichton J, Simwaka B, Thomson R, Makwiza I, Tolhurst R, Martineau T, Bates I. Towards building equitable health systems in Sub-Saharan Africa: lessons from case studies on operational research. Health Research Policy and Systems 2009, 7:26. 10.1186/1478-4505-7-26, 2789709, 19939279.
27. Buchanan-Smith M. How the Sphere Project Came into Being: A Case Study of Policy-Making in the Humanitarian Aid Sector and the Relative Influence of Research. Working Paper 215 2003, London: ODI.
28. Court J, Hovland I, Young J. Bridging Research and Policy in International Development: Evidence and the Change Process. 2005, London: ITDG.
29. . WHO, UNAIDS Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/ AIDS in Africa. 2000, Geneva: UNAIDS, WHO, UNAIDS.
30. Grimwade K, Gilks C. Cotrimoxazole prophylaxis in adults infected with HIV in low income countries. Current Opinion in Infectious Diseases 2001, 14:507-512. 10.1097/00001432-200110000-00002, 11964869.
31. Maynart M, Lièvre L, Sow PS, Kony S, Gueye NFN, Basséne E, Metro A, Ndoye I, Ba DS, Coulaud JP, et al. Primary Prevention With Cotrimoxazole for HIV-1-Infected Adults: Results of the Pilot Study in Dakar, Senegal. JAIDS Journal of Acquired Immune Deficiency Syndromes 2001, 26:130-136.
32. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, Collaboration U-UPL. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. British Medical Journal 2008, 337:1-7.
33. Government of Malawi The use of VCT plus cotrimoxazole prophylaxis in patients with Tuberculosis in Malawi. Meeting Minutes and Policy Statement Community Health Science Unit (CHSU), Lilongwe, on Tuesday 1 October 2002 2002, Lilongwe, Ministry of Health and Population, Government of Malawi.
34. WHO Report of a "Lessons Learnt" workshop on the six ProTEST pilot projects in Malawi, South Africa and Zambia. 2004, Durban, South Africa WHO, WHO.
35. van Oosterhout JJG, Laufer MK, Graham SM, Thumba F, Perez MA, Chimbiya N, Wilson L, Chagomerana M, Molyneux ME, Zijlstra EE, et al. A Community-Based Study of the Incidence of Trimethoprim-Sulfamethoxazole-Preventable Infections in Malawian Adults Living With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 2005, 39:626-631.
36. Boeree MJ, Harries AD, Zijlstra EE, Taylor TE, Molyneux ME. Co-trimoxazole in HIV-1infection (Letter). The Lancet 1999, 354:334.